Recent health news highlights include China's approval of the first commercial brain-computer interface device, GSK's ...

GSK plc GSK announced that the FDA approved the expanded use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 18 to 49 years who are at a higher risk of ...

Recent health developments include China's approval of a brain-computer interface device, expanded age range for GSK's RSV vaccine by the US FDA, and Stryker's operations disrupted by a cyberattack.

Respiratory syncytial virus (RSV) infection makes an impact on the epithelium that varies with age, promoting asthma in children and chronic obstructive pulmonary disease (COPD) in adults, according ...

Children with asthma who contract respiratory syncytial virus (RSV) may experience more severe illness than children without asthma, based on new data presented at a global conference sponsored by the ...